3-Methyladenine (3-MA)

目录号:S2767 别名: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA)是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。

规格 价格 库存 购买数量  
RMB 579.66 现货
RMB 3010.37 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

    Cells were treated with DMSO, TDCIPP (100 μM) only, or pretreated with 3-MA before treatment with TDCIPP (100 μM). LC3 conversion and beclin-1 and p62 expression were assessed by western blotting at 24 h

    Food Chem Toxicol, 2017, 100:183-196. 3-Methyladenine (3-MA) purchased from Selleck.

  • PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

    A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 3-Methyladenine (3-MA)是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。
靶点
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
体外研究

3-MA对Vps34轻微的偏向性可能是由于Vps34中某个特异性的疏水环形结构可以环绕在3-MA的3-甲基基团外面造成的[1] 。据报道对于正常培养和饥饿处理的癌细胞3-MA都能引起细胞死亡。3-MA还可以不通过抑制自吞噬来抑制细胞迁移和入侵,这表明3-MA 除了抑制自吞噬之外还有其它生物功能。3-MA可以造成半胱天冬酶依赖的细胞死亡,这一功能与它对自吞噬的抑制无关。用5mM 3-MA处理葡萄糖饥饿Hela细胞可降低gfp-lc3阳性细胞比例至23%。3-MA处理细胞12到48小时内 LC3-I 的水平上升而LC3-II 水平下降。LC3-I转为为 LC3-II 的过程被3-MA抑制了。 2.5 mM 或5 mM 3-MA 处理HeLa 细胞一天并不影响细胞存活率, 而 10 mM 3-MA 处理一天会造成细胞存活率下降25.0% 。 2.5, 5 或 10 mM 3-MA 处理细胞两天分别使细胞存活率下降 11.5%, 38.0% 和79.4% 。3-MA 降低细胞存活率的作用具有时间和剂量依赖特性。3-MA 明显缩短nocodazole诱导的前中期阻断时间[2]。3-MA 通过抑制自吞噬来抑制SU11274诱导的细胞死亡[3]。 在野生型MEF细胞中延长 3-MA处理时间 (最多 9 小时) 明显造成 LC3 I 到 II 转换。延长 3-MA处理时间会明显增加GFP-LC3的聚集而wortmannin不具有此功能。3-MA介导的LC3 转换和游离 GFP 释放是ATG7依赖的。 3-MA处理会导致 p62 蛋白水平明显升高。即使在Atg5−/− 的MEF细胞中3-MA 也会使p62 水平升高,就像在DOX介导的ATG5缺失的细胞中一样 。3-MA以不同方式抑制 I 型和 III型 PI3K。与野生型细胞相比,在Tsc2−/−细胞中3-MA诱导的 LC3 I 到 LC3 II 转换过程大幅下降。3-MA会破坏mTOR复合物1的拮抗自吞噬功能[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPyN41O NWHsT2xCOmh? NV;ERXdsTE2VTx?= NYXWRVdqemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= NWHTbWk4OjV5MU[1OlE>
A549  M1myV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X2PVNuVQ>? NF7ZO4IzcA>? M4PiOWROW09? MXjy[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E NHf2TFMzPTdzNkW2NS=>
95D NFHmN3RCeG:ydH;zbZMhSXO|YYm= MkjNOY1O M37Gc|Jp MWXEUXNQ MYXpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? NFL2VG0zPTdzNkW2NS=>
A549  NF;OWYNCeG:ydH;zbZMhSXO|YYm= MXS1cW0> MWmybC=> NGLBc|VFVVOR NITU[WlqdmirYnn0d{BDTE2FLXnu[JVk\WRiYYDvdJRwfGmlIHPlcIwh\GWjdHi= NVvaO|VMOjV5MU[1OlE>
NBL-W-S  NX\GOJV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHvPVIydU1? NY\hR|lyPmh? M3zxWIVvcGGwY3XzJGdCVlRvNkGgeI95cWOrdIm= M2O2XVI2OzJ|MkKy
NBL-W-S  NIKwSlRCeG:ydH;zbZMhSXO|YYm= NIf3[W0ydU1? MlnPOog> NFPvVplqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBISU6WLU[x NHjWfmUzPTN{M{KyNi=>
A2780cp  NWLze5I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\TNY1O NU\YXnJ6OWh? NHLpeoRqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NXvOdWtWOjV|MkK2PVQ>
A549  NX72RXRMTnWwY4Tpc44hSXO|YYm= MoTPOY1O NIfVcmwzcA>? MVXzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= NH[5SHYzPTJ6NU[yPC=>
H157 NYLzfVdCTnWwY4Tpc44hSXO|YYm= NEe2O2M2dU1? NFHkdo4zcA>? MUHzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= NGLSe|kzPTJ6NU[yPC=>
MDR NHrsXmtCeG:ydH;zbZMhSXO|YYm= Ml3TNVBuVQ>? MljaOog> MkGwd5Rz\W6pdHjlcpMhfGinIIDve4VzKG:oIHHueIlk[W6lZYKg[JJ2\3N? NHHMS4ozPTBzOUewNS=>
HT-29  Mk\wRZBweHSxc3nzJGF{e2G7 NX2zXXRqOW2P MXO0PIg> NVfCOGpkTE2VTx?= MU\lcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> NXPROpJmOjR6NEKxOVg>
Microglia  NWPxb3dwSXCxcITvd4l{KEG|c3H5 NE\Fbnk2dU1? NHn2VXMzPGh? MXHk[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= NIrxVpozPDhzOE[wNS=>
A2780cp MV;BdI9xfG:|aYOgRZN{[Xl? NVHPXHFuOi53bV2= MYqxbC=> M{fIb4RlUDKR NUDGXZFk\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NIHudVUzPDhzN{m0Oi=>
HepG2 MlrwSpVv[3Srb36gRZN{[Xl? M37iVFVuVQ>? MUC0bC=> MXfpcoNz\WG|ZYOgTGwhemWuZXHz[S=> MYeyOFcyOzV6Nx?=
A549 MkTtRZBweHSxc3nzJGF{e2G7 MWG1cW0> M37vPFQ5cA>? NF3uZ|Vl\WO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubDDk[YF1cCCjbnSg[ZhxemW|c3nvckBt\X[nbIOgc4Yh[2G|cHHz[U0{NCCEZXPsbY4uOSCjbnSgUGM{NUmL MlLCNlQ4ODZ|MEO=
U2OS NHLGWWZCeG:ydH;zbZMhSXO|YYm= MYixNI1O MXuyOIg> NUfDVFdCcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 NEXJe5ozPDZ|OUCxNy=>
Saos-2 MoXBRZBweHSxc3nzJGF{e2G7 NUnWRldTOTCvTR?= MkjENlRp NIXTPJhqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? NVP3[XFGOjR4M{mwNVM>
A549 M2LvNmFxd3C2b4Ppd{BCe3OjeR?= Mn7pNVBuVQ>? NGj6V2M1QGh? MnzBZYNk\WyncnH0[ZMhfGinIILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JHBVYA>? NVz0SGw5OjR4Mk[3NlI>
HCT116  MlqxRZBweHSxc3nzJGF{e2G7 MVS1cW0> MnfYNlRp MXnlcohidmOnczD0bIUh[XCxcITvd4l{KGmwZIXj[YQh[nliYYDp[4VvcW5? MmL6NlQ3OjZ3MkK=
HGC-27 MYHGeY5kfGmxbjDBd5NigQ>? NHzifmQyOG2P NWD0bWJDOWh? NVvR[4M4cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGyxc4OgZpkhWkGGMECxJI9zKE2NLUKyNFY> NVrHeJVuOjR2MU[zOFk>
U2OS  MYnGeY5kfGmxbjDBd5NigQ>? M4XuVlAvPS9zbV2= Mn\4OFhp M1fLd4lv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NWjub3dHOjR|NUizOFI>
MG-63 NV;mclZ1TnWwY4Tpc44hSXO|YYm= M{HsVVAvPS9zbV2= NEPZWWQ1QGh? NYHjVHNscW6mdXPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MY[yOFM2QDN2Mh?=
MG-63 NEfKOWNCeG:ydH;zbZMhSXO|YYm= MoDtNE42NzGvTR?= MUWzNog> MlX6[Y5p[W6lZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?= M4L4bFI1OzV6M{Sy
MG-63 M1uxfmFxd3C2b4Ppd{BCe3OjeR?= M4n4clExdU1? MW[xNog> NWnmW|Z{\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NXrJZoxmOjR|NUizNFE>
NTUB1 MYDBdI9xfG:|aYOgRZN{[Xl? M4nkOVVuVQ>? MYOxMlVp M1PwPZBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? MoP2NlQ{PDlzN{[=
T24 M13R[2Fxd3C2b4Ppd{BCe3OjeR?= NHX0WVE2dU1? NWDGd4RHOS53aB?= NGPqW5lxd3SnboTpZZRmeyClZXzlZ495cWJvaX7keYNm\CCjcH;weI9{cXN? MUiyOFM1QTF5Nh?=
SGC-7901  M2S5SGFxd3C2b4Ppd{BCe3OjeR?= M3P1RlJuVQ>? MkHzNYg> NVTNUG1pcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= NGm1OYczPDN{MUO0NC=>
SMMC-7721 MkHJRZBweHSxc3nzJGF{e2G7 M1jEeFJuVQ>? MX:xbC=> NGfJRnZqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= NV24Xm9UOjR|MkGzOFA>
ECSCs  MYrBdI9xfG:|aYOgRZN{[Xl? M2DwbFExdU1? MkHvOIg> NF\DR4Fl\WO{ZXHz[ZMhemGyYX35Z4lvNXS{ZXH0[YQh[XCxcITvd4l{ NEXM[oUzPDNzOUGwPS=>
MCF-7  MV3GeY5kfGmxbjDBd5NigQ>? MWqxNI1O NVPvVmhROjSq NILF[FNqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgZ4hmdW:2aHXyZZB6KGS{dXfz NVWzTmtuOjR|MUW1O|g>
UOK257 MWLBdI9xfG:|aYOgRZN{[Xl? MkLYOY1O M2jLTFNp NIrNdVdmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li NIHBRZgzPDNyNU[wOC=>
ACHN-5968 Mk\NRZBweHSxc3nzJGF{e2G7 NWfadHVFPW2P Mkm1N4g> NFn2fHBmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li M{ez[FI1OzB3NkC0
Huh7 M2fqVWFxd3C2b4Ppd{BCe3OjeR?= NHiwPXMzdU1? NFLQT|MyOmh? MkiwSG1UVw>? M1TBbolvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo Mkn2NlQzQTd|MEC=
Hep3B NInMWWhCeG:ydH;zbZMhSXO|YYm= M3\pfVJuVQ>? MYSxNog> MlKxSG1UVw>? Mn[4bY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= MXWyOFI6PzNyMB?=
RKO MV;GeY5kfGmxbjDBd5NigQ>? M1\PfFJuVQ>? NVPwN5p4OWh? NYjBOm91TE2VTx?= MlfW[Y5p[W6lZYOgZ4VtdCCmZXH0bEBjgSCpZXzkZY5idXmlaX6= MUCyOFI6OTd5Nx?=
HepG2 E47 NXi3dXh3TnWwY4Tpc44hSXO|YYm= MX:yMlVuVQ>? M2DYe|Q5cA>? MlnybY5kemWjc3XzJJRp\SC2b4jpZ4l1gSCxZjDBRUwhSlORLDDhcoQhS0OuNB?= MY[yOFI4Ozd|OB?=
LoVo  NXLvXHlvSXCxcITvd4l{KEG|c3H5 MnPpOY1O MV:0PIg> MXjlcohidmOnczDER2EucW6mdXPl[EBieG:ydH;zbZMv NVjURVZSOjR{MEG4NVI>
WiDr NEPSdGJHfW6ldHnvckBCe3OjeR?= NY\OeoNmOTCvTR?= NG[2Rm4ycA>? M2DBe4lvcGmkaYTzJHBESkxvaX7keYNm\CCOQ{OgTWkh\XiycnXzd4lwdg>? MoHyNlQyQTB2OEm=
H1299  MVXGeY5kfGmxbjDBd5NigQ>? NV7Q[mdyOTCvTR?= MXG0bC=> NInETWtqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MX2yOFE4OzJyOB?=
H460 M1XaUmZ2dmO2aX;uJGF{e2G7 MnnmNVBuVQ>? Mk\lOIg> NETZVI1qdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MV[yOFE4OzJyOB?=
A549 NH\2UFNHfW6ldHnvckBCe3OjeR?= NVzoOFZMOTCvTR?= NHXGelA1cA>? MWfpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBqenKjZHnheIlwdg>? MYmyOFE1Ojd|NR?=
Hep3B MVfBdI9xfG:|aYOgRZN{[Xl? MlvVOY1O M124S|I1cA>? MVfheJRmdnWjdHXzJHRPTi4QsTDwdo91\WO2aX;uJIFo[Wmwc4Sgd4VzfW1ic4ThdpZifGmxbj3t[YRq[XSnZDDhdI9xfG:|aYO= NEm5TFQzPDB4Nk[5Ny=>
SMMC-7721 MWPBdI9xfG:|aYOgRZN{[Xl? NH3LS|I2dU1? NH;LdVUzPGh? NGjXNY5ifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> M362N|I1ODZ4Nkmz
HO8910 M1fpNmFxd3C2b4Ppd{BCe3OjeR?= NEXpWVIyOG2P MXWxNog> M4HkZ4VvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq NInBVWkzOzl6M{[xNC=>
MCF7 NUDCU3BNTnWwY4Tpc44hSXO|YYm= MVO1cW0> MmrZNlRp MXjpcoNz\WG|ZYOgR5VQKGmwZIXj[YQh[2WubDDk[YF1cA>? NETmblYzOzl4Mk[yPS=>
HONE-1  NEjBWXBHfW6ldHnvckBCe3OjeR?= NEXB[II2dU1? MW[xbC=> MonPdoVxemW|c3XzJFZzNW2nZHnheIVlKFKRUzDwdo9lfWO2aX;u NV\lWZdLOjN6OUKzOVg>
HeLa M333SmZ2dmO2aX;uJGF{e2G7 NFTpd4YyOG2P MVuybC=> NIDYNpJ{fXCycnXzd4V{KEyFMzDJTUBmgHC{ZYPzbZNwdg>? M1XGb|I{QDZ2N{O4
HepG2 MlfYSpVv[3Srb36gRZN{[Xl? NVXFS4hYOTCvTR?= MlLuNlRp NGLPOYpqdmirYnn0d{B{cVSLR1HSMUBidmRiSFLTV{1qdmS3Y3XkJIF2fG:yaHHnfS=> NITROFIzOzhzN{C0NC=>
SH-SY5Y NXLYSoZQTnWwY4Tpc44hSXO|YYm= NEfRO|UydU1? NEXLbZEzPGh? M1LURolvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDUU2NR MoPkNlM4PDNzNEi=
SH-SY5Y NGLpSYNCeG:ydH;zbZMhSXO|YYm= MVi1cW0> MVGxbC=> M331ZoFjd2yrc3jld{Bk\Wyjc4Tyc4whdmW3cn;wdo91\WO2aY\lJIVn\mWldB?= MmXTNlM3OTl|OUW=
PC12  NYDXNWdiTnWwY4Tpc44hSXO|YYm= M2\V[FExdU1? NWTUboM2OjSq Ml\oe4F1\XJ? MURCpIlvcGmkaYTzJINpgW2xdIL5dJNqdi2uaXvlJJBzd3SnYYPvcYFtKGGldHn2bZR6Ng>? M4e0SlI{PjB|OUe5
OV2008 NEfXcGpCeG:ydH;zbZMhSXO|YYm= MkHNOY1O M3ftbVI1cA>? Mm\tZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? NFfkSYQzOzV7MkK4NS=>
A2780 Mo\qRZBweHSxc3nzJGF{e2G7 NYDTcWdDPW2P M{fWW|I1cA>? NGOze2xkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= MYSyN|U6OjJ6MR?=
Saos-2  NF\BOnZCeG:ydH;zbZMhSXO|YYm= M3zqVFFuVQ>? M3fIVFk3cA>? NX3EOlNScW6lcnXhd4V{KGOnbHyg[IVifGhiaX7keYNm\CCkeTDQR3g> MVKyN|U3OzF5MR?=
1321N1 MUnDfZRwfG:6aXPpeJkhSXO|YYm= NHT3fmI2dU1? NV\WfnVQOjSq M4DTVJBzd3SnY4TzJINmdGxiYXfhbY5{fCCSQ16tbY5lfWOnZDD0c5hq[2m2eR?= MlH0NlM2OjV{NkW=
SH-SY5Y NHyzTJZEgXSxdH;4bYNqfHliQYPzZZk> NITCUIw2dU1? NY\2NG12OjSq NEjSd5BqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 M2\DdFI{PTJ3Mk[1
HT-29  MnzSSpVv[3Srb36gRZN{[Xl? MVWxcW0> MoXnOFgwQT[q NYrJdJA5cW6qaXLpeJMhSU2SSzDpcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> MUGyN|UxQDJ5Mh?=
OR6 MX3GeY5kfGmxbjDBd5NigQ>? NIP5[5MyOG2P MknQO|Jp NUDZeZB1e3WycILld5NmeyCKQ2[gdoVxdGmlYYTpc44h[W6mIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MnvINlM{QTV6N{W=
Hela  NXzxWWdITnWwY4Tpc44hSXO|YYm= MoP1OY1O MojXNlRp M2nsc4lvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> NGnSdlUzOzN7NU[3PS=>
MCF-7  NWH6WYVsTnWwY4Tpc44hSXO|YYm= NITHSHc2dU1? M4TyZlI1cA>? M2nXSYlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> NHXYPFQzOzN7NU[3PS=>
HUVECs MkL3SpVv[3Srb36gRZN{[Xl? NWHEPZdKO22P MlnwNlRp NIjzNFhjdG:la4OgeIhmKHC{b4TlZ5RqfmViZX\m[YN1KG:oIILld5ZmemG2cn;sJIJ6KGmwaHnibZRqdmdiYYX0c5Bp[We7 M4\QclI{OzV6OUK4
T24 M2nBd2Z2dmO2aX;uJGF{e2G7 MlK3NVBuVQ>? NUD0UFUzOWh? NEfaNWtz\WS3Y3XzJJRp\SClbHXheoFo\SCxZjDMR|Mh[W[2ZYKgZoFq[2GuaX6geJJm[XSvZX70 MUiyN|M2PDB6MB?=
U251MG  MVLGeY5kfGmxbjDBd5NigQ>? NGe2SZc{dU1? NXPY[WE2OWh? M2nofZN2eHC{ZYPz[ZMhVEN|LVnJJJBzd3SnaX6g[ZhxemW|c3nvci=> NI\1[ZAzOzN|OE[xPC=>
GTL-16  NFTIbXdCeG:ydH;zbZMhSXO|YYm= MVq1cW0> NIDOPZEzPGh? M3mwW5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYYOgZ49ueGG{ZXSgeI8h[2WubIOgeJJm[XSnZDD3bZRpKE2HVDDpcohq[mm2b4Lz NXTYeFIyOjN|MUO0PVA>
T-47D M3jMSmZ2dmO2aX;uJGF{e2G7 NGjFNIoyOG2P NGrqZpgzcA>? NWmzVlJIcW6qaXLpeJMh[XW2b4DoZYd6KHC{b3Pld5Mh[W6mIHnuZ5Jm[XOnczDyZZBidXmlaX6gbY5lfWOnZDDhdI9xfG:|aYO= NFXHb5QzOzNyMECyOi=>
PaCa44 M3zkWGFxd3C2b4Ppd{BCe3OjeR?= M4LpdVIvPW2P NYHsW5EyOWh? NWri[YdNemWmdXPld:Kh\2WwaYDpck1u\WSrYYTl[EBieG:ydH;zbZM> Mm\xNlMyOjRzMUK=
MDA-MB231 MnuwSpVv[3Srb36gRZN{[Xl? M3TUSlVuVQ>? M3\BdlFp M2TnUYlv[3KnYYPld{Bz\XO4ZYLheJJwdC2vZXTpZZRm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> NVfiU|BFOjNyOEi4OVA>
HeLa M2HLZWFxd3C2b4Ppd{BCe3OjeR?= MYOxNI1O MXSybC=> NX7EXoJC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0cYVvfCC5aYToJHBGUQ>? NU[3SYZwOjNyMECxN|U>
SK-HEP-1 NIDYNGtCeG:ydH;zbZMhSXO|YYm= M1ewUFExdU1? M2fjZlFp NF[5VJBxem:2ZXP0d{Bi\2GrboP0JIF2fG:yaHHnfUBidmRiaX7keYNmeyCjcH;weI9{cXNiaX6gZpVn[Wyrbj30doVifGWmIHPlcIx{ MWmyNlg2QDZ2OR?=
HepG2 MXvBdI9xfG:|aYOgRZN{[Xl? M13OR|NuVQ>? M{\DOFVp M{izfZJm\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDRSJM> MX:yNlg{PjV7NR?=
MCF-7  Mm\ySpVv[3Srb36gRZN{[Xl? M{HP[|JuVQ>? NETo[IUzPGh? M1XQVolvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= MWKyOFk4ODZ5Nh?=
MDA-MB-231 NXnkdFhWTnWwY4Tpc44hSXO|YYm= MY[ycW0> M3vjTlI1cA>? MVnpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi M3TIfFI1QTdyNke2
MCF-7  M1OzSWZ2dmO2aX;uJGF{e2G7 M2mxUlJuVQ>? M4\qcFQ5cA>? NGCw[Wpxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? NITsUoEzPDl5ME[3Oi=>
MDA-MB-231 MX;GeY5kfGmxbjDBd5NigQ>? MV[ycW0> NUfsZXNIPDiq NFrhUGNxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? NHrsW4IzPDl5ME[3Oi=>
PANC-1  M2TLOGFxd3C2b4Ppd{BCe3OjeR?= MnS2NY1O MXq0PIg> NGXQeZhFVVOR NVK5d4w2\W6qYX7j[ZMh[m:{dHX6c41q[i2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? M2DNcFI1QDR{MUW4
MDA-MB 231 NVTq[2kzSXCxcITvd4l{KEG|c3H5 MlTVOY1O MkfINE42cA>? NY\oNmZqdW:mdXzheIV{KFSxY3;tbY7DtsLiaX7keYNm\CCjcH;weI9{cXN? MXmyOFg{ODd6MR?=
Microglia  M4ntN2Fxd3C2b4Ppd{BCe3OjeR?= NWfGNlVRPW2P NX;6OIZNOjSq MoDQ[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo NX7zPXU6OjR6MUi2NFE>
A2780cp MoCwRZBweHSxc3nzJGF{e2G7 MmnhNk42dU1? M1fOb|Fp MXnk[GgzVw>? NGHxOYpmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MnGwNlQ5OTd7NE[=
HepG2 NWnPfWxyTnWwY4Tpc44hSXO|YYm= NYrPV3AyPW2P MX60bC=> M3e3b4lv[3KnYYPld{Bk\WyudXzhdkBt\X[nbIOgc4YhUE{EoB?= MX:yOFcyOzV6Nx?=
U2OS MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXnUYIyOG2P MY[yOIg> NEn4OnFqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUBFd3h? NYK2d5VNOjR4M{mwNVM>
HCT116 MkHDRZBweHSxc3nzJGF{e2G7 MkPPOY1O Mn\PNlRp NXrjXVRDTE2VTx?= NYPsTIpb\W6qYX7j[ZMh[XCrZ3XubY4ucW6mdXPl[EBk\WyuIHTlZZRp MY[yOFYzPjV{Mh?=
MCF-7  MYTBdI9xfG:|aYOgRZN{[Xl? NET6RnAxNjGvTR?= NFPzRYY3cA>? MlTs[Y5p[W6lZYOgd4lzfGmwb3ytbY5lfWOnZDDhdI9xfG:|aYO= MUGyNlc2OTl6OR?=
PC-3  NELNeIVCeG:ydH;zbZMhSXO|YYm= NGHmZWYzdU1? MVeybC=> NXO5[YIzcW6lcnXhd4V{KE:UST3pcoR2[2WmIHPlcIwh\GWjdHi= M37zZlIzPzR3NUiw
U251  MV;BdI9xfG:|aYOgRZN{[Xl? NV\mfoR4PW2P M4O2S|I1cA>? MUnpcoNz\WG|ZYOgV|EucW6mdXPl[EBk\WyuIHTlZZRp MVuyNlU4QTd6OB?=
HeLa  M4fmNmFxd3C2b4Ppd{BCe3OjeR?= MnHhOY1O M1rsXlI1cA>? M1P3N4lv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZ4VtdCCmZXH0bC=> M1:yflIzPTR3MUK4
A549 NWTGN|JXTnWwY4Tpc44hSXO|YYm= MWKwMlFuVQ>? M3zOOlI1cA>? MXjzeZBxemW|c3XzJHNWOTF{N{StbY5lfWOnZDDj[YxtKGSnYYTo MUCyNlQ3Pjl4MB?=
pDCs NE\mdJhHfW6ldHnvckBCe3OjeR?= MUWxNI1O NFTDUWgxNjWq M3zweeKhemWmdXPld{B1cGViaX7keYN1cW:wIH;mJGlHVi4QsTDifUB{e1KQQUSw M3yydVIzOzl4NUm5
BGC-823 NXTHblhkTnWwY4Tpc44hSXO|YYm= NYD0U2FFPW2P MUGybC=> MYTpcohq[mm2czD0bIUhemG2ZTDv[kBifXSxcHjh[4lkKGOnbHzz MU[yNlMzOjF3Mh?=
U937 MYPGeY5kfGmxbjDBd5NigQ>? M{XrSVJuVQ>? M1rmZVEzcA>? MnfL[IVkemWjc3XzJJRp\SCjdYTvdIhi\3licnH0bY/DqA>? MUSyNlE2PTF3MB?=
Marc-145 MXTGeY5kfGmxbjDBd5NigQ>? NFnYfoc2dU1? NVPCfGdQOTJxMkSvN|Zp NVX2bGs6emWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u M2fBXlIzOTF7OUCw
HBx  M{LZXGFxd3C2b4Ppd{BCe3OjeR?= NH3NcWgyOG2P NH7Oeo41QGh? NYnSTWN2TE2VTx?= MWLpcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> MUGyNlAzODB5OB?=
MCF-7 NIftVVZHfW6ldHnvckBCe3OjeR?= NE\OdIIyOG2P MV:0PIg> NHPo[HNjdG:la4OgZZV1d3CqYXf5JIlv\HWlZXSgZpkh[m:{dHX6c41q[g>? NF3KeGszOTl|MUmzOy=>
RMPI8226  MUTGeY5kfGmxbjDBd5NigQ>? NWH1W|IzPW2P NUDFd3pwOWh? MnXyd5VxeHKnc4Pld{B1cGVibHX2[Ywhd2ZiYYX0c5Bp[We7IIXu[IVzKG63dILp[Y51KGSncHzleIlwdg>? MViyNVkyPTZ{MB?=
PC12/TetOn MY\GeY5kfGmxbjDBd5NigQ>? MXewMlEwOW2P NWT2bHd3OTiq MkW1cIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB? MoXmNlE6ODZ4NUm=
HeLa  MYnDfZRwfG:6aXPpeJkhSXO|YYm= MmK1No1O Mli1NlRp MXrpcohq[mm2ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kB{cWyrYnnubY4hfG9iSHXMZUBk\Wyucz6= M2nITlIyQDd3M{i1
Jurkat MlyxSpVv[3Srb36gRZN{[Xl? Ml3aNVBuVQ>? MmnMNYg> NUj2UI9o\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFMz3JTUBidmRidHjlJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NUDPbXN[OjF6NkSwN|c>
K562 M33wWWZ2dmO2aX;uJGF{e2G7 NW\XNFRFOTCvTR?= M3Lrb|Fp MXzk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| MYKyNVg3PDB|Nx?=
Nara-H Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL4OY1O MnTOOFhp MX3lcohidmOnczD0[Y1{cXKxbHnteZNu\WSrYYTl[EB{fXCycnXzd4lwdiCxZjDOZZJiNUhiY3XscEBxem:uaX\ldoF1cW:w MV2yNVgxPTB|Mx?=
HUVECs MXTGeY5kfGmxbjDBd5NigQ>? NYjtZW1MOTCvTR?= M2jCWFAvPWh? Mly5[IVkemWjc3XzJJRp\SCDR1WtRnNCcW6mdXPl[EBifXSxcHjh[5khdGW4ZR?= MYmyNVQ3QDV7Mh?=
HepG2 MkXHRZBweHSxc3nzJGF{e2G7 M37KTFJuVQ>? NFu3fI4ycA>? M3fxUIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxiZHXheIg> M{eyblIyPDV|Nkmx

... Click to View More Cell Line Experimental Data

体内研究 3-Methyladenine (3-MA)可以通过对磷酸肌醇3磷酸激酶(PI3K) 的作用来阻断自吞噬, 而PI3K的活性对于自噬体形成早期膜池的成核和组装是必须的。与SAH 处理组相比3-MA并不会改变出血的程度。与SAH +对照成分组相比经过3-MA预处理后会明显加重神经病学症状。3-MA处理会减少自吞噬发生[5]。 相反地,在SAH + 3-MA组里 断裂的半胱天冬酶表达量明显上调,与此一致的是与SAH + 对照成分组相比,SAH + 3-MA组中右脑皮层里原位末端标记阳性细胞数量明显增多[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[4]
+ 展开

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
细胞实验:[2]
+ 展开
  • Cell lines: HeLa 细胞系
  • Concentrations: 1-10 mM
  • Incubation Time: 3 分钟
  • Method: 用台盼蓝染色法分析细胞存活率(如HeLa细胞)。简言之, 经过3-MA处理后将贴壁的与漂浮的细胞都用PBS( pH 7.4)重悬,密度控制在每毫升1-2×106。加入等体积的0.4% 台盼蓝并彻底混匀。室温孵育3分钟后用血细胞计数器对细胞计数分析。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 体重 300-350 g 的成年雄性Sprague–Dawley 大鼠
  • Formulation: 生理盐水配制
  • Dosages: 400 nM
  • Administration: 脑室给药
    (Only for Reference)

溶解度 (25°C)

体外 Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 149.15
化学式

C6H7N5

CAS号 5142-23-4
稳定性 powder
in solvent
别名 NSC 66389

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • 回答:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)供应商 | 采购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)价格 | 3-Methyladenine (3-MA)生产 | 订购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID